Double-Blind Comparison of Escitalopram and Duloxetine in??the??Acute Treatment of Major??Depressive Disorder

Abstract

These findings suggest that escitalopram is better tolerated and at least as effective as the serotonin-norepinephrine reuptake inhibitor duloxetine in the treatment of major depressive disorder.

Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants

“…Agomelatine, escitalopram, mirtazapine and venlafaxine were significantly more efficacious than fluoxetine in achieving a 50 % reduction in baseline HDRS or MADRS score (Fig. 4a) 64). Mirtazapine and venlafaxine were also superior to duloxetine, paroxetine and sertraline.…”

Efficacy and tolerability of milnacipran and escitalopram: a comparative study among patients of depression

“…[6][7][8][9][10] It was also found to be non inferior and significantly better tolerated than the two SNRIs, Venlafexine and Duloxetine. [11][12][13] Milnacipran is the most balanced SNRI which blocks the reuptake of both serotonin and norepinephrine equally.…”

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

“…Data analyses were based on standard commercial statistical programs (Stata.8 1 , StataCorp, College Station, TX; Statview.5 1 , SAS, Cary, NC). Brecht et al, 2007;Khan et al, 2007;Lee et al, 2007;Nierenberg et al, 2007;Raskin et al, 2007Raskin et al, , 2008aWade et al, 2007) (Tables 2 and 3). Age averaged 44.1 AE 6.7 years; one trial selected patients averaging 73 years of age (reported in Raskin et al, 2007Raskin et al, , 2008a Abbreviations: DLX, duloxetine; PBO, placebo; SRI, serotonin-reuptake inhibitor comparators (FLX…”

“…FDA approval of DLX for the treatment of MDD was supported by at least 17 controlled trials, including two proof-of-concept studies, two short-term dose-finding trials, four phase-III short-and long-term trials, and one relapse-prevention trial (Goldstein et al, , 2004Detke et al, 2002aDetke et al, ,b, 2004Company, 2004c,f, 2006e;Brannan et al, 2005;Burt et al, 2005;Perahia et al, 2006aPerahia et al, ,b, 2008Brecht et al, 2007;Khan et al, 2007;Lee et al, 2007;Nierenberg et al, 2007;Raskin et al, 2007Raskin et al, , 2008aWade et al, 2007). At least three of these trials remain unpublished in peer-reviewed journals; two did not find statistical superiority of relatively low doses of DLX over PBO (Eli Lilly and Company, 2004c,f).…”